Jazz Pharmaceuticals plc

History

Year	Detail
2003	Bruce Cozadd co-founded Jazz Pharmaceuticals.
2005	The company acquired Orphan Medical, which developed and commercialized the central nervous system depressant Xyrem (sodium oxybate).
2012	Jazz Pharmaceuticals closed the business combination of Jazz Pharmaceuticals Inc. and Azur Pharma plc. The two companies have combined to create Jazz Pharmaceuticals plc, a specialty biopharmaceutical company based in Dublin, Ireland. Following the closing, Jazz Pharmaceuticals plc has around $60 million in outstanding ordinary shares on a fully diluted basis.
2014	Jazz Pharmaceuticals plc and Aerial BioPharma LLC signed an agreement under which Jazz Pharmaceuticals has acquired rights to ADX-N05, a novel compound in clinical development for treating excessive daytime sleepiness in patients with narcolepsy.
2014	Jazz Pharmaceuticals plc and Gentium S.p.A. announced the commencement of the European commercial launch of Defitelio, the first licensed product for the treatment of severe hepatic veno-occlusive disease in patients over one month of age undergoing hematopoietic stem cell transplantation (HSCT) therapy.
2017	Jazz Pharmaceuticals and ImmunoGen Inc. entered a collaboration and option agreement to develop and commercialize antibody-drug conjugate products. As part of the agreement, Jazz will pay ImmunoGen an upfront payment of $75 million.
2018	Jazz Pharmaceuticals plc and The University of Texas MD Anderson Cancer Center entered into a five-year collaboration agreement to evaluate therapies for multiple hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes.
2019	Jazz Pharmaceuticals plc signed a definitive agreement under which the company has acquired Redx Pharma's (Redx) pan-RAF inhibitor program to treat RAF and RAS mutant tumors potentially.
2020	Jazz Pharmaceuticals plc signed a new research collaboration agreement with Redx Pharma plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase (MAPK) pathway.
2021	Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) approved Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for treating idiopathic hypersomnia in adults.
2022	Jazz Pharmaceuticals plc and Zymeworks Inc. entered into a licensing agreement under which Jazz will acquire development and commercialization rights to Zymeworks' zanidatamab across all indications in the United States, Europe, Japan, and all other territories except for those Asia/Pacific territories previously licensed by Zymeworks.
2023	Jazz Pharmaceuticals plc expanded the support of the American Heart Association to deliver an in-depth understanding of the cardiovascular risks associated with these debilitating disorders to the sleep disorder community.